J Cancer 2017; 8(13):2487-2491. doi:10.7150/jca.18824
Upregulation of Serum miR-10b Is Associated with Poor Prognosis in Patients with Melanoma
Department of Plastic and Reconstructive Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China
Bai M, Zhang H, Si L, Yu N, Zeng A, Zhao R. Upregulation of Serum miR-10b Is Associated with Poor Prognosis in Patients with Melanoma. J Cancer 2017; 8(13):2487-2491. doi:10.7150/jca.18824. Available from https://www.jcancer.org/v08p2487.htm
Aberrant expression of microRNAs (miRNAs) are believed to play a central role in the initiation and development of cancer. The aim of our study was to determine the clinical significance of serum miR-10b in melanoma. A total of 85 and 30 serum samples were obtained from patients with melanoma and healthy volunteers respectively. qRT-PCR was performed to evaluate the expression level of miR-10b in the melanoma cell lines and the serum samples from the participants. Then the clinical significance of serum miR-10b was further determined. Our results showed that the expression level of miR-10b was significantly increased in metastasis melanoma cells and melanoma patients compared to their respective controls. In addition, serum miR-10b expression level was able to discriminate melanoma patients from healthy volunteers as well differentiate melanoma patients at different clinical stage with high accuracy. Moreover, upregulation of serum miR-10b was positively associated with enhanced lymph node metastasis, advanced clinical stage and a shortened survival rate. Finally serum miR-10b was an independent prognostic factor for melanoma. Collectively, our study suggests that serum miR-10b level is upregulated in melanoma and associated with poor prognosis. It may be used as a potential prognostic biomarker for melanoma.
Keywords: Serum, miR-10b, melanoma, Prognosis.